CRNX - Crinetics Pharmaceuticals, Inc.

38.9
-1.350   -3.470%

Share volume: 883,216
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$40.25
-1.35
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.12%
1 Month
12.07%
3 Months
-29.21%
6 Months
-3.78%
1 Year
24.40%
2 Year
-10.45%
Key data
Stock price
$38.90
P/E Ratio 
0.00
DAY RANGE
$38.68 - $40.58
EPS 
-$4.95
52 WEEK RANGE
$25.83 - $57.99
52 WEEK CHANGE
$20.17
MARKET CAP 
2.509 B
YIELD 
N/A
SHARES OUTSTANDING 
104.705 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
1.77
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$891,559
AVERAGE 30 VOLUME 
$1,140,608
Company detail
CEO: Scott R. Struthers
Region: US
Website: crinetics.com
Employees: 210
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Crinetics Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism.

Recent news